

References

L-58

1. Grendys Jr EC, Fiorica JV, Orr Jr JW, et al. Overview of a chemoresponse assay in ovarian cancer. *ClinTransl Oncol*. 2014; 16(9): 761-769.
2. Krivak TC, Lele S, Richard S, et al. A chemoresponsive assay for prediction of platinum resistance in primary ovarian cancer. *AM J Obstet Gynecol*. 2014; 211: 68.e1-8.
3. Tian C, Sargent DJ, Krivak TC, et al. Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: Further analysis of a prospective study. *BJC*. 2014;111:1-8.
4. Garajová I, Le Large TY, Frampton AE, et al. Molecular Mechanisms Underlying the Role of MicroRNAs in the Chemoresistance of Pancreatic Cancer. *BioMed Research International*.2014:1-17.
5. Gerlach MM, Merz F, Wichmann G, et al. Slice cultures from head and neck squamous cell carcinoma: a novel test system for drug susceptibility and mechanisms of resistance. *Brit J of Cancer*. 2014; 110: 479–488.
6. National Comprehensive Cancer Network (NCCN). Guidelines clinical practice guidelines in oncology. V 1.2015. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. *NCCN*. 2015.
7. Hsieh C, Chen Y, Huang S, Wang H, Wu M. The Effect of Primary Cancer Cell Culture Models on the Results of Drug Chemosensitivity Assays: The Application of Perfusion Microbioreactor System as Cell Culture Vessel. *Biomed Research International*. January 14, 2015;2015:1-10.
8. National Comprehensive Cancer Network (NCCN). Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. Version 2016.
9. Gautam P, Kaarhinen L, et al. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. *Molecular Cancer*, 2016;15(34):1-16.
10. Bhagwandin S, Naffouje S, et al. Utility of chemoresponse assay in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy, *Ann Surg Oncol*. 2015;22:2573-2577.
11. Richard S, Wells A, et al. Use of ChemoFx® for identification of effective treatments in epithelial ovarian cancer. *Plos Currents*. 2015 July 13;7.
12. Tanigawa N, Yamaue H, Ohyama S, et al. Exploratory phase II trial in a multicenter setting to evaluate the clinical value of a chemosensitivity test in patients with gastric cancer (JACCRO-GC 04, Kubota memorial trial). *Gastric Cancer*. Apr 2016;19(2):350-360.
13. Bosserman L, Rogers K, Willis C, et al. Application of a drug-induced apoptosis assay to identify treatment strategies in recurrent or metastatic breast cancer. *PLoS One*. 2015;10(5):e0122609.
14. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. Version 2.2017.
15. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Version 3.2017.